Thrombosis Risk
Thrombosis Risk - Related Videos
10:37
Ferric Chloride-induced Murine Thrombosis Models
0 Views •
Cited by 56 •
2016
We report a refined procedure of the ferric chloride (FeCl3)-induced thrombosis models on carotid and mesenteric artery as well as vein, characterized efficiently using intravital microscopy to monitor time to occlusive thrombi formation.
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
0 Views •
Cited by 5 •
2015
The goal of this study is to use magnetic resonance venography with long-circulating gadolinium-based contrast agent and direct thrombus imaging for quantitative evaluation of DVT volume in a multicenter, clinical trial setting. Inter- and intra-observer variability assessments were conducted, and reproducibility of the protocol was determined.
04:34
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
0 Views •
Cited by 28 •
2011
The mouse complete stasis model of inferior vena cava thrombosis yields quantifiable amounts of vein wall tissue and thrombus. It has proven useful for evaluating interactions between the vein wall and the occlusive thrombus and in assessing the progression from acute to chronic inflammation.
07:26
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
0 Views •
Cited by 49 •
2015
The FeCl3 induced thrombosis model in mice is described herein. A method to monitor thrombus growth by intravital microscopy observation on a mesenteric vessel and by blood flow measurement in the carotid artery is presented.
06:03
Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
0 Views •
Cited by 39 •
2011
The electrolytic induction of endothelial activation to the internal surface of the Inferior Vena Cava results in venous type thrombus formation due to endothelial activation and partial blood stasis, two components of Virchow's triad.
FAQs
Tumor cells and inflammatory signals can shift the coagulation system toward clot formation. At the same time, damage to the blood vessel lining may expose conditions that further activate coagulation and platelets. These interacting mechanisms are important in cancer research because they show that thrombosis risk can arise from coordinated tumor, inflammatory, vascular, and blood-cell changes rather than from a single cause.
Platelet activity and coagulation promote clot formation, whereas clot breakdown limits persistence of the clot. Cancer-related changes can disturb this balance by increasing platelet activity, activating coagulation, or reducing the relative effectiveness of breakdown. Examining these processes together helps researchers understand why circulation may become obstructed and how cancer-associated clotting differs among biological contexts.
A healthy circulation depends on a balance between forming clots when needed and breaking them down afterward. When cancer-related influences favor formation over breakdown, clots may persist or grow and interfere with blood flow. This balance provides a useful mechanistic framework for studying thrombosis risk and for considering how preventive or therapeutic strategies might alter coagulation without ignoring clot-resolution processes.
Treatment-related changes may contribute to thrombosis risk by altering coagulation, platelet activity, or the condition of blood vessels. The overview identifies treatment as one of several influences alongside tumor cells and inflammation, so risk assessment must consider the treatment context rather than focus only on the cancer itself. This perspective is relevant when evaluating complications during treatment and recovery.
Assessment focuses on how cancer, inflammatory signals, vascular injury, platelet activity, coagulation, and treatment-related changes combine to influence clot formation. In research, this evaluation supports investigation of cancer-associated coagulation and comparison of preventive strategies. Clinically relevant interpretation also helps inform individualized decisions about anticoagulant therapy, particularly when thrombosis could complicate diagnosis, treatment, or recovery.
Cancer-associated clotting may produce venous thromboembolism, including deep vein thrombosis or pulmonary embolism. These outcomes matter because an obstructing clot can impair circulation and cause tissue injury. Studying which cancer-related mechanisms favor these events helps researchers evaluate prevention and understand how thrombotic complications may affect diagnostic decisions, treatment courses, and recovery.